Chorordin-like 1は,臓がん細胞の移動と侵入を阻害する:BMP4/SMAD経路の関与
PubMedで要約を見る
まとめ
この要約は機械生成です。この研究では,CHRDL1が臓がんでダウンレギュレーションされ,腫瘍抑制剤として作用することが判明しました. 過剰発現したCHRDL1は,BMP4/ SMAD経路を遮断することで,癌細胞の移転と転移を抑制する.
科学分野
- 腫瘍学
- 分子生物学
- 生物化学
背景
- 臓がんは致命的な悪性腫瘍で 生存率は低い.
- CHRDL1はBMP4の抗体であり,他のがんでは腫瘍抑制作用が知られているが,臓がんではその役割は不明である.
研究 の 目的
- 臓がんにおけるCHRDL1の機能と背後にあるメカニズムを調査する.
- CHRDL1が診断や治療の標的になる可能性があるかどうかを判断する.
主な方法
- レンチウイルスベクターを用いた臓がん細胞系 (PANC- 1 , SW1990) のCHRDL1過剰発現
- 細胞増殖,移動,粘着の評価;BMP4抗体の検証
- TCGA,IHC,RT-qPCRを用いた患者組織におけるCHRDL1発現の分析と予後との相関.
- 肺転移に対するCHRDL1の効果を評価するインビボ試験.
主要な成果
- CHRDL1の発現は臓がん組織で著しく低下し,予後が悪いと相関しています.
- CHRDL1の過剰発現は,臓がん細胞の移動と結合を抑制したが,増殖を抑制しなかった.
- CHRDL1はBMP4/ SMAD信号伝達経路を阻害し,SMAD1/5/9のリン酸化を減少させ,RUNX2の発現を減少させた.
- CHRDL1はBMP4誘発の悪性行動と肺転移を vivoで抑制した.
結論
- CHRDL1は,BMP4/ SMAD経路を阻害することで,臓がんにおける腫瘍抑制剤として機能する.
- CHRDL1の発現の低下は,臓がんの進行,移住,侵入,転移に寄与する.
- CHRDL1は,臓がん治療における潜在的な治療標的である.
関連する概念動画
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...

